The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B

Rheumatology

Volumn 47, Issue 11, 2008, Pages 1732-1733

  Rodríguez Escalera, Carlo ^a   Fernandez nebro A ^b  

^a Hospital Comarcal de Melilla   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA2A INTERFERON; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RITUXIMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; VIRUS LOAD; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; SPONDYLITIS, ANKYLOSING;

EID: 54449096535     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken362     Document Type: Letter

References (4)

1. Wendling D. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008;75:510-1.
2. Dorner T. Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells. J Rheumatol Suppl 2006;77:3-11.
3. Boulos P, Dougados M, Macleod SM, Hunsche E. Pharmacological treatment of ankylosing spondylitis: A systematic review. Drugs 2005;65:2111-27.
4. Ferreiro Seoane JL, Gómez Rodríguez N, Formigo Rodríguez E, Martínez Isla A, Antón Badiola I. [The coexistence of rheumatoid arthritis, ankylosing spondylitis and intestinal necrotizing vasculitis]. An Med Interna 1993;10:452-4.